Video
Dr. Wee on androgen receptor inhibitors for the management of nonmetastatic CRPC
Author(s):
Video Player is loading.
Christopher Wee, MD, a genitourinary medical oncologist at Cleveland Clinic, discusses available androgen receptor inhibitors for the treatment of patients with nonmetastatic castration-resistant prostate cancer, including apalutamide (Erleada) darolutamide (Nubeqa) and enzalutamide (Xtandi). He also explains what is still needed to optimize the use of these agents in this space.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
Selecting Between Receptor Pathway Inhibitors for mHSPC
Related Content
